Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 20 November 2023 – On 6 November 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 30 billion to be executed during a 12-month period beginning 1 February 2023.
Under the programme initiated 6 November 2023, Novo Nordisk will repurchase B shares for an amount up to DKK 4.1 billion in the period from 7 November 2023 to 29 January 2024.
Since the announcement of the programme, the following transactions have been made:
|Number of B shares (of DKK 0.10)||Average purchase price||Transaction value, DKK|
|Accumulated, last announcement||440,000||310,784,175|
|13 November 2023||110,000||708.41||77,924,787|
|14 November 2023||113,000||692.59||78,263,126|
|15 November 2023||113,000||676.25||76,416,161|
|16 November 2023||110,000||678.91||74,679,694|
|17 November 2023||110,000||694.32||76,374,652|
|Accumulated under the programme||996,000||694,442,596|
The details for each transaction made under the share repurchase programme are published on novonordisk.com.
Transactions related to Novo Nordisk’s incentive programmes have resulted in a net transfer from Novo Nordisk of 134,052 B shares in the period from 7 November 2023 to 16 November 2023. The shares in these transactions were not part of the Safe Harbour repurchase programme.
With the transactions stated above, Novo Nordisk owns a total of 49,000,054 B shares of DKK 0.10 as treasury shares, corresponding to 1.1% of the share capital. The total amount of A and B shares of DKK 0.10 in the company is 4,510,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK 30 billion during a 12-month period beginning 1 February 2023. As of 17 November 2023, Novo Nordisk has since 1 February 2023 repurchased a total of 45,103,778 B shares of DKK 0.10 at an average share price of DKK 589.08 per B share of DKK 0.10 equal to a transaction value of DKK 26,569,527,394.
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 61,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com,Facebook, Instagram, X, LinkedIn andYouTube.
Contacts for further information
|Ambre James-Brown |
+45 3079 9289
|Elizabeth DeLuca (US)|
+1 609 580 9868
|Daniel Muusmann Bohsen|
+45 3075 2175
|Jacob Martin Wiborg Rode|
+45 3075 5956
|David Heiberg Landsted|
+45 3077 6915
|Mark Joseph Root (US)|
+1 848 213 3219
|Sina Meyer |
+45 3075 6656 firstname.lastname@example.org
|Frederik Taylor Pitter |
+45 3075 8259 email@example.com
Company announcement No 79 / 2023
AttachmentsTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
New wording of AB Akola Group Articles of Association is registered, the name of the company changes and the authorized capital is increased5.12.2023 07:30:00 CET | Press release
On 4 December 2023, a new wording of the Articles of Association of AB Akola Group (hereinafter – “the Company“) was registered in the Register of Legal Entities (enclosed). AB Linas Agro Group has changed name to AB Akola Group. The new wording of the Articles of Association was approved on 27 October 2023 during the Annual General Meeting of Company's Shareholders together with the decision to increase the authorised capital of the Company by EUR 1,764,518.92, issuing 6,084,548 new ordinary registered book-entry shares. The newly issued shares were subscribed for by employees and/or members of the corporate bodies of the Company who had entered into a share option agreement with the Company in 2018 and 2020 and provided the Company with a notice of exercise of the option in 2023. The new shares are granted free of charge, and they are paid by the Company from the reserve set up by the Company for share granting. Additional information: Mažvydas Šileika, CFO of AB Akola Group Mob. +37
Roche announces positive Phase III results for inavolisib combination in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation5.12.2023 07:00:00 CET | Press release
Phase III (INAVO120) results show that inavolisib in combination with palbociclib and fulvestrant significantly improved progression-free survival in the first-line settingPIK3CA mutations, found in approximately 40% of HR-positive breast cancers, are linked to tumour growth, disease progression, and treatment resistance1,2 Data will be shared with health authorities and presented at an upcoming medical meeting Basel, 5 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive results from the Phase III INAVO120 study of the investigational therapy, inavolisib, in combination with palbociclib (Ibrance®) and fulvestrant as a potential first-line treatment option for people with PIK3CA-mutated, hormone receptor (HR)-positive, HER2-negative, endocrine-resistant, locally advanced or metastatic breast cancer. The study met its primary endpoint of progression-free survival (PFS), demonstrating a statistically significant and clinically meaningful improvement compared to pal
Moleac’s NeuroAiD™II Improves Post-Concussion Symptoms, Quality of Life, and Mood after a Mild Traumatic Brain Injury5.12.2023 04:41:56 CET | Press release
With its targeted multimodal approach, NeuroAiD™II offers a broad range of therapeutic benefits to TBI patients.NeuroAiD™II was well-tolerated by TBI patients with a favourable safety profile. SINGAPORE, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Moleac announced promising results from the SAMURAI double-blind study in patients with mild traumatic brain injury (mTBI) receiving a 6-month course of NeuroAiD™II. In the study, the NeuroAiD™II group showed significant improvement in their post-concussion symptoms, quality of life and mood, compared to those in the placebo group. Presented by Professor Valery Feigin at the World Congress of Neurology, last October in Montreal, these results expand the list of therapeutic benefits of NeuroAiD™II observed in previous clinical trials conducted on TBI patients, and confirm its favourable safety profile1, 2, 3. In the SAMURAI study, mTBI patients underwent a series of tests assessing various types of impairments and their recovery over time. For cognition
Nokia comments on AT&T vendor plans5.12.2023 03:30:00 CET | Press release
Nokia Corporation Stock Exchange Release 5 December 2023 at 4:30 EET Nokia comments on AT&T vendor plans Espoo, Finland – Nokia has a wide-ranging relationship with AT&T, supplying products and services across wireless, wireline and other network technologies, alongside similar relationships with other major North American network operators. Nokia is aware of AT&T’s plans to commit to an Open RAN deployment in collaboration with other vendors over the next five years. As a result, Nokia now expects revenue from AT&T in Mobile Networks will decrease over the next 2-3 years. AT&T accounted for 5-8% of Mobile Networks net sales year-to-date in 2023. The already announced action Nokia is taking to reduce its cost base is expected to partially mitigate the impact of AT&T’s decision. Nokia expects Mobile Networks to remain profitable over the coming years but this decision would delay the timeline of achieving double digit operating margin by up to 2 years. Nokia has invested heavily in the
Canadian Government Awards New Funding to General Fusion5.12.2023 02:00:00 CET | Press release
RICHMOND, Canada, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Today, General Fusion announced that Canada’s Strategic Innovation Fund (SIF) has awarded CA$5 million to support research and development to advance the company’s Magnetized Target Fusion (MTF) demonstration at its Richmond headquarters. Called LM26, this ground-breaking machine will progress major technical milestones required to commercialize zero-carbon fusion power by the early to mid-2030s. The funds are an addition to the existing contribution agreement with SIF, to support the development of General Fusion’s transformational technology. Fusion energy is the ultimate clean energy solution. It is what powers the sun and stars. It’s the process by which two light nuclei merge to form a heavier one, emitting a massive amount of energy. By 2100, the production and export of the Canadian industry’s fusion energy technology could provide up to $1.26 trillion in economic benefits to Canada. Additionally, fusion could completely offset